clinical trial · NCT07313813
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company·phase1·active not recruiting·n = 20
Type 2 Diabetes Mellitus (T2DM)Dulaglutide
brief summary
The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal. Ultrasound devices will be used to check the stomach content after a test meal. The study can last approximately 28 weeks.
started
Dec 29, 2025
primary completion
Aug 1, 2026
completion
Aug 1, 2026
last updated
Apr 16, 2026
official title
A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol